In Vivo Hydrodynamic Delivery of cDNA Encoding IL-2: Rapid, Sustained Redistribution, Activation of Mouse NK Cells, and Therapeutic Potential in the Absence of NKT Cells
Open Access
- 15 July 2005
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 175 (2) , 693-699
- https://doi.org/10.4049/jimmunol.175.2.693
Abstract
In the present study, we have tested the ability of hydrodynamically delivered IL-2 cDNA to modulate the number and function of murine leukocyte subsets in different organs and in mice of different genetic backgrounds, and we have evaluated effects of this mode of gene delivery on established murine tumor metastases. Hydrodynamic administration of the IL-2 gene resulted in the rapid and transient production of up to 160 ng/ml IL-2 in the serum. The appearance of IL-2 was followed by transient production of IFN-γ and a dramatic and sustained increase in NK cell numbers and NK-mediated cytolytic activity in liver and spleen leukocytes. In addition, significant increases in other lymphocyte subpopulations (e.g., NKT, T, and B cells) that are known to be responsive to IL-2 were observed following IL-2 cDNA plasmid delivery. Finally, hydrodynamic delivery of only 4 μg of the IL-2 plasmid to mice bearing established lung and liver metastases was as effective in inhibiting progression of metastases as was the administration of large amounts (100,000 IU/twice daily) of IL-2 protein. Studies performed in mice bearing metastatic renal cell tumors demonstrated that the IL-2 cDNA plasmid was an effective treatment against liver metastasis and moderately effective against lung metastasis. Collectively, these results demonstrate that hydrodynamic delivery of relatively small amounts of IL-2 cDNA provides a simple and inexpensive method to increase the numbers of NK and NKT cells, to induce the biological effects of IL-2 in vivo for use in combination with other biological agents, and for studies of its antitumor activity.Keywords
This publication has 32 references indexed in Scilit:
- Cancer Immunotherapy: A Treatment for the MassesScience, 2004
- Immunoregulatory T cells in tumor immunityCurrent Opinion in Immunology, 2004
- NK cell and DC interactionsPublished by Elsevier ,2004
- Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal CancerJournal of Clinical Oncology, 2003
- Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor LymphocytesScience, 2002
- Bendamustine in the treatment of non-Hodgkin's lymphoma: Results and future perspectivesSeminars in Oncology, 2002
- A Critical Role for Natural Killer T Cells in Immunosurveillance of Methylcholanthrene-induced SarcomasThe Journal of Experimental Medicine, 2002
- IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedsideExpert Opinion on Biological Therapy, 2002
- Induction of tumor-specific T cell memory by NK cell–mediated tumor rejectionNature Immunology, 2001
- Intravenous Injection of Naked DNA Encoding Secreted flt3 Ligand Dramatically Increases the Number of Dendritic Cells and Natural Killer Cellsin VivoHuman Gene Therapy, 2000